The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

We are implementing a digital health intervention, mPATH-Cloud, in one community health center. Patients who receive a link to the mPATH-Cloud website will be able to view a video designed to help them choose the colorectal cancer (CRC) screening test that is best for them. Patients who select colonoscopy will receive a referral from their primary care provider. Patients who do not select colonoscopy will receive a FIT in the mail. We will assess the feasibility and effectiveness of implementing mPATH-Cloud in combination with mailed FIT outreach for increasing CRC screening among community health center patients.

No guidelines or interventions for patients and their family caregivers exist to support patient adherence to a new medication (venetoclax) and their quality of life. Our research team seeks to understand the real experience and care needs of patients and their family caregivers with the new AML treatment. With the information we learn from this study, we will be able to develop an effective support program for patients with AML and their family caregivers to manage their symptoms at home and improve their quality of life.

The DNA that we can test from a nasal swab, can help us determine a patient's lung cancer risk. For patients with new lung nodules found on CT scans, we are offering this nasal swab test and collecting data on how physicians use test results to help assess risk and determine treatment strategies.

To establish the recommended Phase II dose of a flavored preparation of orally administered irinotecan (VAL-413) when given in combination with temozolomide for 5 consecutive days.

The purpose of the study is to determine how the Cancer Prevention and Control Research Network (CPCRN) researchers and their community partners are operationalizing the nine health equity Principles adopted by the network. The examples, acquired through in-depth interviews, will be used to develop a technical assistance toolkit for CPCRN and the general research community.

The purpose of this research study is to assess the patient-level, healthcare provider/system-level, and community-level barriers to resolving abnormal mammograms and initiation of treatment of breast cancer in the 3 geographic regions of North Carolina: the greater Charlotte area, the Northwest, and the Northeast. These areas include the following counties: Anson, Cabarrus, Cleveland, Gaston, Lincoln, Mecklenburg, Stanly, Union, Edgecombe, Halifax, Nash, Northampton, Wilson , Ashe, Alleghany, Surry, Stokes, Watauga, Wilkes, Yadkin, Forsyth, Avery, Caldwell, Alexander, Iredell, Davie, Davidson, Burke, Catawba, and Rowan. These barriers can include obtainment of biopsies and other diagnostic procedures for resolving abnormal mammograms abnormalities or breast symptoms, access to care providers after breast cancer diagnosis, and initiation of appropriate surgical, chemotherapy, and radiation treatments after diagnosis.

Using carefully constructed case vignettes and a survey of oncology providers across a spectrum of settings, we sought to characterize early trends in internalization of the girentuximab PET-CT into care.

The study purpose is to find out if (a) it's possible to deliver healthy frozen meals to homes of children receiving chemotherapy, and (b) the meals are acceptable to the children and their families.

The purpose of this research study is to monitor how well patients with fatty liver disease can follow clinician-recommended diet and exercise before their liver surgery. Our goal is to understand patient adherence to weight-related goals, weight loss, physical activity, and improved liver health. You are being asked to be in the study because you are a patient with fatty liver disease planning to have liver surgery.